Access Program Information
The objective of this study is to provide early access to daratumumab treatment and collect
additional safety data while the medication is not commercially available or available
through another protocol for subjects with multiple myeloma who have received at least 3
prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent
(IMiD) or whose disease is double refractory to both a PI and an IMiD.